Replimune's Promising Results for Acral Melanoma at ESMO 2025

Woburn, Sunday, 19 October 2025.
Replimune’s RP1 combined with Nivolumab achieved a 44% response rate in acral melanoma, a rare and aggressive skin cancer, with a median response duration of 11.9 months.